Skip to main content
Premium Trial:

Request an Annual Quote

Quest Extends Tender Offer for Celera Shares for Final Time

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today extended its tender offer for Celera's shares to May 10, 5 p.m. EDT.

The offering, made in connection with Quest's $671 million purchase of Celera, is being made through Quest's wholly owned subsidiary, Spark Acquisition, and will not be extended further, Quest said.

Its initial tender offering for Celera expired last week and a subsequent offering was tendered and expired on Friday.

Quest said that more than 880,000 shares of Celera's common stock had been tendered during the subsequent tender offering and Spark has accepted for payment all tendered shares. Spark now owns nearly 52 million shares of Celera common stock, or about 62 percent of Celera's outstanding shares of common stock and 59 percent of Celera's outstanding shares on a fully diluted basis.

Quest will pay the same $8 per share consideration that was initially offered. Following the completion of the subsequent offering period, if Spark obtains 90 percent of more of Celera's outstanding shares, Quest will effect a short-form merger with Celera, and all remaining Celera shareholders will receive the same $8 per share price in cash.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.